You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFurosemide
Accession NumberDB00695  (APRD00608, DB07799)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. [PubChem]

Structure
Thumb
Synonyms
2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
Frusemide
Furosemid
Furosemida
Furosemide
Furosemidu
Furosemidum
Lasix (tn)
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-furosemidetablet80 mgoralAvanstra Inc2011-08-112014-08-21Canada
Ava-furosemidetablet40 mgoralAvanstra Inc2011-08-112014-08-21Canada
Ava-furosemidetablet20 mgoralAvanstra Inc2011-08-112014-08-21Canada
Bio-furosemidetablet40 mgoralBiomed Pharma2003-04-11Not applicableCanada
Bio-furosemidetablet20 mgoralBiomed Pharma2003-04-11Not applicableCanada
Dom-furosemidetablet20 mgoralBiomed Pharma2003-10-142013-08-02Canada
Dom-furosemidetablet40 mgoralBiomed Pharma2003-10-142013-08-02Canada
Furosemidetablet20 mg/1oralAvera Mc Kennan Hospital2015-06-09Not applicableUs
Furosemidetablet20 mg/1oralA S Medication Solutions Llc1981-10-19Not applicableUs
Furosemideinjection10 mg/mLintravenousAmerican Regent, Inc.1990-09-30Not applicableUs
Furosemidetablet20 mg/1oralCardinal Health2008-03-26Not applicableUs
Furosemidetablet20 mgoralSanis Health Inc2010-06-15Not applicableCanada
Furosemideinjection, solution10 mg/mLintramuscular; intravenousHospira, Inc.1982-05-28Not applicableUs
Furosemidetablet20 mg/1oralCardinal Health2010-10-12Not applicableUs
Furosemidetablet40 mg/1oralCardinal Health2008-03-26Not applicableUs
Furosemidetablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-11-30Not applicableUs
Furosemidetablet80 mgoralSanis Health Inc2010-06-15Not applicableCanada
Furosemidetablet20 mg/1oralMylan Institutional Inc.1997-02-06Not applicableUs
Furosemideinjection20 mg/2mLintramuscular; intravenousMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-02-01Not applicableUs
Furosemidetablet40 mg/1oralMajor Pharmaceuticals2008-03-26Not applicableUs
Furosemidetablet40 mg/1oralRoxane Laboratories, Inc1983-11-10Not applicableUs
Furosemidetablet40 mg/1oralREMEDYREPACK INC.2013-05-23Not applicableUs
Furosemideinjection, solution10 mg/mLintramuscular; intravenousCardinal Health2010-07-13Not applicableUs
Furosemidetablet40 mg/1oralPreferred Pharmaceuticals, Inc.2013-03-20Not applicableUs
Furosemidetablet80 mg/1oralA S Medication Solutions Llc1981-10-19Not applicableUs
Furosemideinjection10 mg/mLintravenousAmerican Regent, Inc.1990-09-30Not applicableUs
Furosemidetablet20 mg/1oralRoxane Laboratories, Inc1983-11-10Not applicableUs
Furosemidetablet20 mg/1oralREMEDYREPACK INC.2013-05-23Not applicableUs
Furosemideinjection, solution10 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2000-07-12Not applicableUs
Furosemidetablet20 mg/1oralMajor Pharmaceuticals2008-03-26Not applicableUs
Furosemideinjection, solution10 mg/mLintramuscular; intravenousCardinal Health2010-07-13Not applicableUs
Furosemidetablet40 mg/1oralAphena Pharma Solutions Tennessee, Llc1981-10-19Not applicableUs
Furosemidetablet40 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-28Not applicableUs
Furosemideinjection10 mg/mLintravenousAmerican Regent, Inc.1990-09-30Not applicableUs
Furosemidetablet20 mg/1oralREMEDYREPACK INC.2013-05-22Not applicableUs
Furosemidetablet40 mg/1oralClinical Solutions Wholesale1983-11-10Not applicableUs
Furosemidetablet40 mg/1oralSandoz Inc1981-10-19Not applicableUs
Furosemidetablet40 mg/1oralRoxane Laboratories, Inc1983-11-10Not applicableUs
Furosemideinjection, solution10 mg/mLintramuscular; intravenousCardinal Health2010-07-13Not applicableUs
Furosemidetablet80 mg/1oralDAVA Pharmaceuticals, Inc.1982-07-27Not applicableUs
Furosemidetablet40 mg/1oralSafecor Health, LLC2014-09-30Not applicableUs
Furosemidetablet40 mg/1oralMylan Pharmaceuticals Inc.1987-08-27Not applicableUs
Furosemidetablet20 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Furosemidetablet20 mg/1oralClinical Solutions Wholesale1983-11-10Not applicableUs
Furosemidetablet20 mg/1oralSandoz Inc1981-10-19Not applicableUs
Furosemidetablet20 mg/1oralRoxane Laboratories, Inc1983-11-10Not applicableUs
Furosemidetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Furosemidetablet40 mg/1oralDAVA Pharmaceuticals, Inc.1982-07-27Not applicableUs
Furosemidetablet20 mg/1oralAphena Pharma Solutions Tennessee, Llc1983-11-10Not applicableUs
Furosemidetablet20 mg/1oralMylan Pharmaceuticals Inc.1981-08-27Not applicableUs
Furosemidetablet20 mg/1oralREMEDYREPACK INC.2013-03-14Not applicableUs
Furosemidetablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-11-10Not applicableUs
Furosemidetablet20 mg/1oralCardinal Health1981-08-27Not applicableUs
Furosemidetablet80 mg/1oralSandoz Inc1981-10-19Not applicableUs
Furosemidetablet20 mg/1oralDAVA Pharmaceuticals, Inc.1982-07-27Not applicableUs
Furosemidetablet20 mg/1oralAphena Pharma Solutions Tennessee, Llc1981-10-19Not applicableUs
Furosemidetablet20 mg/1oralIVAX Pharmaceuticals, Inc.1983-11-30Not applicableUs
Furosemideinjection, solution10 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
Furosemidetablet40 mg/1oralA S Medication Solutions Llc1981-10-19Not applicableUs
Furosemidetablet40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-11-30Not applicableUs
Furosemideinjection, solution10 mg/mLintramuscular; intravenousCardinal Health2010-07-13Not applicableUs
Furosemidetablet40 mgoralSanis Health Inc2010-06-15Not applicableCanada
Furosemideinjection, solution10 mg/mLintramuscular; intravenousCardinal Health2013-11-19Not applicableUs
Furosemidetablet40 mg/1oralCardinal Health2010-10-12Not applicableUs
Furosemidetablet40 mg/1oralCardinal Health1981-08-27Not applicableUs
Furosemidetablet80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1981-10-19Not applicableUs
Furosemidetablet40 mg/1oralMylan Institutional Inc.1997-02-06Not applicableUs
Furosemidetablet40 mg/1oralContract Pharmacy Services Pa2010-04-12Not applicableUs
Furosemidetablet80 mg/1oralMajor Pharmaceuticals2008-03-26Not applicableUs
Furosemidetablet40 mg/1oralIVAX Pharmaceuticals, Inc.1983-11-30Not applicableUs
Furosemideinjection, solution10 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Furosemide 20 Tabtablet20 mgoralPro Doc Limitee1980-12-31Not applicableCanada
Furosemide 20mg Tabletstablet20 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Furosemide 40mgtablet40 mgoralPro Doc Limitee1977-12-31Not applicableCanada
Furosemide 40mg Tabtablet40 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Furosemide 40mg Tabletstablet40 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Furosemide Inj 10mg/mlliquid10 mgintramuscular; intravenousInternational Medication Systems Ltd.1979-12-311997-08-15Canada
Furosemide Inj USPliquid10 mgintramuscular; intravenousSandoz Canada Incorporated1981-12-31Not applicableCanada
Furosemide Injectionliquid10 mgintramuscular; intravenousOmega Laboratories Ltd2011-06-08Not applicableCanada
Furosemide Injection Sdzsolution10 mgintramuscular; intravenousSandoz Canada Incorporated2012-07-26Not applicableCanada
Furosemide Injection USPsolution10 mgintramuscular; intravenousAlveda Pharmaceuticals Inc2013-08-22Not applicableCanada
Furosemide Injection USPsolution10 mgintravenousHospira Healthcare Corporation1982-12-31Not applicableCanada
Furosemide Specialsolution10 mgintravenousSandoz Canada Incorporated1991-12-31Not applicableCanada
Furosemide Special Injectionliquid10 mgintravenousOmega Laboratories Ltd2011-06-08Not applicableCanada
Furosemide Special Sdzsolution10 mgintravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Furosemide-80 Tab 80mgtablet80 mgoralPro Doc Limitee1995-12-31Not applicableCanada
Furoside Tab 20mgtablet20 mgoralIcn Canada Ltd.1976-12-312005-04-26Canada
Furoside Tab 40mgtablet40 mgoralIcn Canada Ltd.1978-12-312005-04-26Canada
Lasixtablet40 mg/1oralSanofi Aventis U.S. Llc1966-07-01Not applicableUs
Lasixtablet20 mgoralSanofi Aventis Canada Inc1997-04-212014-06-09Canada
Lasixtablet20 mg/1oralValidus Pharmaceuticals LLC1974-05-07Not applicableUs
Lasixtablet80 mg/1oralValidus Pharmaceuticals LLC1978-04-24Not applicableUs
Lasixtablet40 mg/1oralValidus Pharmaceuticals LLC1966-07-01Not applicableUs
Lasixtablet20 mg/1oralSanofi Aventis U.S. Llc1966-07-01Not applicableUs
Lasixtablet80 mg/1oralSanofi Aventis U.S. Llc1966-07-01Not applicableUs
Lasixtablet40 mgoralSanofi Aventis Canada Inc1997-04-212014-06-09Canada
Lasix - Tab 80mgtablet80 mgoralAventis Pharma Inc1997-08-202003-07-22Canada
Lasix 40mg Tabletstablet40 mgoralHoechst Roussel Canada Inc.1995-12-311999-08-11Canada
Lasix 80mg Tabletstablet80 mgoralHoechst Roussel Canada Inc.1994-12-311999-08-11Canada
Lasix Injection 10mg/mlliquid10 mgintramuscular; intravenousHoechst Roussel Canada Inc.1994-12-312000-07-28Canada
Lasix Injection 10mg/ml - Im IVliquid10 mgintramuscular; intravenousHoechst Marion Roussel Canada Inc.1998-11-122001-07-31Canada
Lasix Oral Soln 10mg/mlliquid10 mgoralHoechst Canada Inc.1978-12-311997-08-05Canada
Lasix Oral Solution 10mg/mlsolution10 mgoralSanofi Aventis Canada Inc1996-12-04Not applicableCanada
Lasix Oral Solution 10mg/mlliquid10 mgoralHoechst Roussel Canada Inc.1994-12-311998-08-12Canada
Lasix Parenteral Injliquid20 mgintramuscular; intravenousHoechst Canada Inc.1968-12-311996-08-29Canada
Lasix Parenteral Injection 10mg/mlliquid10 mgintramuscular; intravenousHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Lasix Specialtablet500 mgoralSanofi Aventis Canada Inc1997-08-20Not applicableCanada
Lasix Special Inj 10mg/mlliquid10 mgintravenousHoechst Canada Inc.1976-12-311999-08-11Canada
Lasix Special Tab 500mgtablet500 mgoralHoechst Canada Inc.1976-12-311996-08-29Canada
Lasix Special Tablets 500mgtablet500 mgoralHoechst Roussel Canada Inc.1994-12-311999-08-11Canada
Lasix Tab 20mgtablet20 mgoralHoechst Canada Inc.1974-12-311996-08-29Canada
Lasix Tab 20mgtablet20 mgoralHoechst Roussel Canada Inc.1994-12-311999-08-11Canada
Lasix Tab 80mgtablet80 mgoralHoechst Canada Inc.1977-12-311997-08-05Canada
Lasix Tabs 40 mgtablet40 mgoralHoechst Canada Inc.1966-12-311997-08-05Canada
Ntp-furosemidetablet80 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-furosemidetablet40 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-furosemidetablet20 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-furosemide Tabletstablet20 mgoralNu Pharm Inc2004-12-102012-09-04Canada
Nu-furosemide Tabletstablet40 mgoralNu Pharm Inc2004-03-192012-09-04Canada
Nu-furosemide Tabletstablet80 mgoralNu Pharm IncNot applicableNot applicableCanada
PMS-furosemidetablet40 mgoralPharmascience Inc2003-12-10Not applicableCanada
PMS-furosemidetablet20 mgoralPharmascience Inc2003-12-10Not applicableCanada
Teva-furosemidetablet80 mgoralTeva Canada Limited1988-12-31Not applicableCanada
Teva-furosemidetablet40 mgoralTeva Canada Limited1976-12-31Not applicableCanada
Teva-furosemidetablet20 mgoralTeva Canada Limited1976-12-31Not applicableCanada
Uritol Tabtablet40 mgoralCarter Horner Corp.1976-12-311996-09-09Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Furosemide Tab 20mgtablet20 mgoralApotex Inc1977-12-31Not applicableCanada
Apo Furosemide Tab 40mgtablet40 mgoralApotex Inc1976-12-31Not applicableCanada
Apo Furosemide Tab 80mgtablet80 mgoralApotex Inc1986-12-31Not applicableCanada
Furosemidesolution40 mg/5mLoralCardinal Health1987-04-22Not applicableUs
Furosemideinjection, solution10 mg/mLintravenousClaris Lifesciences, Inc2014-02-06Not applicableUs
Furosemidetablet20 mg/1oralRebel Distirbutors Corp2006-09-18Not applicableUs
Furosemidetablet80 mg/1oralRanbaxy Pharmaceuticals Inc.2009-01-29Not applicableUs
Furosemideinjection, solution10 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Furosemidesolution10 mg/mLoralMorton Grove Pharmaceuticals, Inc.1987-10-02Not applicableUs
Furosemidetablet40 mg/1oralTYA Pharmaceuticals2009-01-29Not applicableUs
Furosemidetablet80 mg/1oralbryant ranch prepack1987-08-27Not applicableUs
Furosemidetablet40 mg/1oralMed Vantx, Inc.2012-03-16Not applicableUs
Furosemidetablet80 mg/1oralREMEDYREPACK INC.2016-02-08Not applicableUs
Furosemidetablet80 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Furosemideinjection10 mg/2mLintramuscular; intravenousRebel Distributors Corp1983-11-30Not applicableUs
Furosemidesolution10 mg/mLoralRoxane Laboratories, Inc1988-07-12Not applicableUs
Furosemidetablet40 mg/1oralSt Marys Medical Park Pharmacy2013-05-09Not applicableUs
Furosemidetablet20 mg/1oralPd Rx Pharmaceuticals, Inc.2006-02-01Not applicableUs
Furosemideinjection10 mg/mLintravenousCardinal Health1990-09-30Not applicableUs
Furosemidetablet40 mg/1oralPhysicians Total Care, Inc.1999-01-04Not applicableUs
Furosemidetablet40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-03-26Not applicableUs
Furosemideinjection, solution10 mg/mLintramuscular; intravenousHospira, Inc.1999-05-28Not applicableUs
Furosemidetablet20 mg/1oralDIRECT RX2014-01-01Not applicableUs
Furosemidetablet20 mg/1oralA S Medication Solutions Llc2004-03-26Not applicableUs
Furosemidetablet40 mg/1oralCardinal Health2011-07-25Not applicableUs
Furosemidetablet80 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-08-22Not applicableUs
Furosemidetablet20 mg/1oralPreferred Pharmaceuticals, Inc.2009-01-29Not applicableUs
Furosemidetablet40 mg/1oralRanbaxy Pharmaceuticals Inc.2009-01-29Not applicableUs
Furosemideinjection, solution10 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc.2001-03-01Not applicableUs
Furosemidetablet40 mg/1oralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Furosemidetablet20 mg/1oralTYA Pharmaceuticals2009-01-29Not applicableUs
Furosemidetablet80 mg/1oralCardinal Health1986-01-24Not applicableUs
Furosemideinjection, solution10 mg/mLintravenousClaris Lifesciences, Inc2014-02-06Not applicableUs
Furosemidetablet40 mg/1oralSTAT Rx USA LLC2006-02-01Not applicableUs
Furosemideinjection, solution10 mg/mLintramuscular; intravenousHospira, Inc.1999-05-28Not applicableUs
Furosemidetablet40 mg/1oralDIRECT RX2014-01-01Not applicableUs
Furosemidetablet40 mg/1oralREMEDYREPACK INC.2011-10-13Not applicableUs
Furosemidetablet40 mg/1oralCardinal Health1983-11-30Not applicableUs
Furosemidetablet40 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-07-25Not applicableUs
Furosemidesolution40 mg/4mLoralPrecision Dose Inc.2012-10-23Not applicableUs
Furosemidetablet40 mg/1oralUnit Dose Services2009-01-29Not applicableUs
Furosemidetablet20 mg/1oralPhysicians Total Care, Inc.2002-11-20Not applicableUs
Furosemidetablet40 mg/1oralAidarex Pharmaceuticals LLC2009-01-29Not applicableUs
Furosemidetablet20 mg/1oralRanbaxy Pharmaceuticals Inc.2009-01-29Not applicableUs
Furosemidetablet80 mg/1oralMylan Institutional Inc.1997-02-06Not applicableUs
Furosemidetablet80 mg/1oralClinical Solutions Wholesale2004-03-26Not applicableUs
Furosemidetablet40 mg/1oralReady Meds2004-03-26Not applicableUs
Furosemidesolution40 mg/5mLoralRoxane Laboratories, Inc1987-04-222016-01-06Us
Furosemidetablet40 mg/1oralCardinal Health1983-11-10Not applicableUs
Furosemideinjection, solution10 mg/mLintravenousClaris Lifesciences, Inc2014-02-06Not applicableUs
Furosemidetablet40 mg/1oralBlenheim Pharmacal, Inc.2013-12-20Not applicableUs
Furosemidetablet20 mg/1oralREMEDYREPACK INC.2015-07-13Not applicableUs
Furosemidetablet40 mg/1oralREMEDYREPACK INC.2011-10-10Not applicableUs
Furosemidetablet20 mg/1oralCardinal Health1983-11-30Not applicableUs
Furosemidetablet20 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-08-22Not applicableUs
Furosemidetablet80 mg/1oralAphena Pharma Solutions Tennessee, Llc1991-03-13Not applicableUs
Furosemidetablet20 mg/1oralUnit Dose Services2009-01-29Not applicableUs
Furosemidetablet40 mg/1oralA S Medication Solutions Llc2004-03-26Not applicableUs
Furosemidetablet20 mg/1oralAidarex Pharmaceuticals LLC2009-01-29Not applicableUs
Furosemidetablet80 mg/1oralMylan Pharmaceuticals Inc.1987-08-27Not applicableUs
Furosemidetablet20 mg/1oralProficient Rx LP2006-02-01Not applicableUs
Furosemidetablet80 mg/1oralIngenus Pharmaceuticals, LLC2011-06-01Not applicableUs
Furosemidetablet40 mg/1oralClinical Solutions Wholesale, Llc2004-03-26Not applicableUs
Furosemidetablet20 mg/1oralReady Meds2004-03-26Not applicableUs
Furosemidetablet80 mg/1oralMc Kesson Contract Packaging2011-08-29Not applicableUs
Furosemidetablet20 mg/1oralCardinal Health1983-11-10Not applicableUs
Furosemideinjection, solution10 mg/mLintravenousClaris Lifesciences, Inc2014-02-06Not applicableUs
Furosemidetablet20 mg/1oralBlenheim Pharmacal, Inc.2013-08-30Not applicableUs
Furosemidetablet40 mg/1oralREMEDYREPACK INC.2015-05-15Not applicableUs
Furosemidetablet20 mg/1oralREMEDYREPACK INC.2011-09-26Not applicableUs
Furosemidetablet80 mg/1oralCardinal Health1987-08-27Not applicableUs
Furosemidetablet80 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2004-10-01Not applicableUs
Furosemidetablet20 mg/1oralRed Pharm Drug Inc.2009-01-29Not applicableUs
Furosemidetablet80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1991-03-13Not applicableUs
Furosemidetablet20 mg/1oralA S Medication Solutions Llc2004-03-26Not applicableUs
Furosemidetablet20 mg/1oralREMEDYREPACK INC.2015-10-20Not applicableUs
Furosemidetablet80 mg/1oralRoxane Laboratories, Inc1986-01-24Not applicableUs
Furosemidetablet40 mg/1oralIngenus Pharmaceuticals, LLC2011-06-01Not applicableUs
Furosemidetablet20 mg/1oralClinical Solutions Wholesale, Llc2009-01-29Not applicableUs
Furosemidetablet80 mg/1oralExcellium Pharmaceutical Inc.2006-02-01Not applicableUs
Furosemidetablet40 mg/1oralMc Kesson Contract Packaging2011-10-11Not applicableUs
Furosemidetablet20 mg/1oralCardinal Health2011-08-22Not applicableUs
Furosemideinjection, solution10 mg/mLintravenousClaris Lifesciences, Inc2014-02-06Not applicableUs
Furosemidetablet80 mg/1oralQualitest Pharmaceuticals2004-03-26Not applicableUs
Furosemidetablet40 mg/1oralProficient Rx LP2006-02-01Not applicableUs
Furosemidetablet80 mg/1oralREMEDYREPACK INC.2015-03-16Not applicableUs
Furosemidetablet20 mg/1oralREMEDYREPACK INC.2011-06-27Not applicableUs
Furosemideinjection10 mg/mLintravenousCardinal Health1990-09-30Not applicableUs
Furosemidetablet20 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2004-10-01Not applicableUs
Furosemidetablet40 mg/1oralContract Pharmacy Services Pa2011-05-01Not applicableUs
Furosemidetablet20 mg/1oralREMEDYREPACK INC.2010-11-012015-12-29Us
Furosemidetablet80 mg/1oralA S Medication Solutions Llc2009-01-29Not applicableUs
Furosemideinjection, solution10 mg/mLintravenousHeritage Pharmaceuticals Inc.2015-06-26Not applicableUs
Furosemidetablet80 mg/1oralRoxane Laboratories, Inc1991-03-13Not applicableUs
Furosemidetablet40 mg/1oralExcellium Pharmaceutical Inc.2006-02-01Not applicableUs
Furosemidetablet20 mg/1oralMc Kesson Contract Packaging2011-10-07Not applicableUs
Furosemideinjection10 mg/mLintravenousPhysicians Total Care, Inc.2005-09-29Not applicableUs
Furosemideinjection, solution10 mg/mLintravenousClaris Lifesciences, Inc2014-02-06Not applicableUs
Furosemidetablet40 mg/1oralQualitest Pharmaceuticals2004-03-26Not applicableUs
Furosemidetablet20 mg/1oralProficient Rx LP2009-01-29Not applicableUs
Furosemidetablet20 mg/1oralIngenus Pharmaceuticals, LLC2011-06-01Not applicableUs
Furosemidetablet20 mg/1oralPd Rx Pharmaceuticals, Inc.2004-03-26Not applicableUs
Furosemidetablet80 mg/1oralCardinal Health2010-10-12Not applicableUs
Furosemidetablet40 mg/1oralPd Rx Pharmaceuticals, Inc.2006-02-01Not applicableUs
Furosemidetablet40 mg/1oralRebel Distirbutors Corp2006-09-18Not applicableUs
Furosemidetablet40 mg/1oralbryant ranch prepack2009-01-29Not applicableUs
Furosemidetablet40 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Furosemidetablet20 mg/1oralSt Marys Medical Park Pharmacy2013-05-09Not applicableUs
Furosemidetablet40 mg/1oralMed Vantx, Inc.2009-01-29Not applicableUs
Furosemideinjection10 mg/mLintravenousCardinal Health1990-09-30Not applicableUs
Furosemidetablet20 mg/1oralbryant ranch prepack2009-01-29Not applicableUs
Furosemidetablet40 mg/1oralContract Pharmacy Services Pa2011-02-08Not applicableUs
Furosemidesolution40 mg/5mLoralPrecision Dose Inc.2016-01-28Not applicableUs
Furosemidetablet80 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Furosemideinjection, solution10 mg/mLintravenousHeritage Pharmaceuticals Inc.2014-09-02Not applicableUs
Furosemidesolution40 mg/5mLoralRoxane Laboratories, Inc1987-04-22Not applicableUs
Furosemideinjection, solution10 mg/mLintravenousREMEDYREPACK INC.2015-03-07Not applicableUs
Furosemidetablet40 mg/1oralREMEDYREPACK INC.2010-11-22Not applicableUs
Furosemidetablet80 mg/1oralPhysicians Total Care, Inc.1997-03-03Not applicableUs
Furosemidetablet20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-03-26Not applicableUs
Furosemidetablet20 mg/1oralQualitest Pharmaceuticals2004-03-26Not applicableUs
Furosemidetablet40 mg/1oralProficient Rx LP2009-01-29Not applicableUs
Furosemidetablet40 mg/1oralA S Medication Solutions Llc2004-03-26Not applicableUs
Furosemidetablet40 mg/1oralPd Rx Pharmaceuticals, Inc.2004-03-26Not applicableUs
Furosemidetablet20 mg/1oralExcellium Pharmaceutical Inc.2006-02-01Not applicableUs
Furosemidetablet40 mg/1oralPreferred Pharmaceuticals, Inc.2012-07-25Not applicableUs
Lasixtablet40 mg/1oralPreferred Pharmaceuticals Inc.2016-04-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DiurapidMibe Jena
DiurinMylan
DiurmesselBiomep
EutensinSanofi
FrumexNot Available
FrusenexNot Available
FrusolRosemont
Furo-PurenActavis
SegurilSanofi
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7LXU5N7ZO5
CAS number54-31-9
WeightAverage: 330.744
Monoisotopic: 330.007719869
Chemical FormulaC12H11ClN2O5S
InChI KeyInChIKey=ZZUFCTLCJUWOSV-UHFFFAOYSA-N
InChI
InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
IUPAC Name
4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
SMILES
NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentAminobenzenesulfonamides
Alternative Parents
Substituents
  • Aminobenzenesulfonamide
  • Halobenzoic acid
  • 4-halobenzoic acid
  • 4-halobenzoic acid or derivatives
  • Aminobenzoic acid or derivatives
  • Aminobenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Phenylalkylamine
  • Substituted aniline
  • Benzoyl
  • Aralkylamine
  • Secondary aliphatic/aromatic amine
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Vinylogous amide
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Furan
  • Oxacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.
PharmacodynamicsFurosemide, a sulfonamide-type loop diuretic structurally related to bumetanide, is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome.
Mechanism of actionFurosemide, a loop diuretic, inhibits water reabsorption in the nephron by blocking the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. This is achieved through competitive inhibition at the chloride binding site on the cotransporter, thus preventing the transport of sodium from the lumen of the loop of Henle into the basolateral interstitium. Consequently, the lumen becomes more hypertonic while the interstitium becomes less hypertonic, which in turn diminishes the osmotic gradient for water reabsorption throughout the nephron. Because the thick ascending limb is responsible for 25% of sodium reabsorption in the nephron, furosemide is a very potent diuretic.
Related Articles
Absorption60% absorbed in patients with normal renal function
Volume of distributionNot Available
Protein binding95% bound to plasma proteins
Metabolism

Only a small amount is hepatically metabolized to the defurfurylated derivative, 4-chloro-5-sulfamoylanthranilic acid.

SubstrateEnzymesProduct
Furosemide
Not Available
4-chloro-5-sulfamoylanthranilic acidDetails
Route of eliminationFurosemide is excreted in urine. Significantly more furosemide is excreted in urine following the I.V. injection than after the tablet or oral solution.
Half life2 hours
ClearanceNot Available
ToxicityProfound diuresis may cause fluid and electrolyte depletion. Excessive dehydration and potassium depletion may occur. Excessive diuresis may cause rapid weight loss, orthostatic hypotension or acute hypotensive episodes. May also cause tinnitus, reversible or permanent hearing loss or reversible deafness.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Furosemide Action PathwayDrug actionSMP00115
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9155
Blood Brain Barrier-0.8833
Caco-2 permeable-0.6436
P-glycoprotein substrateNon-substrate0.8775
P-glycoprotein inhibitor INon-inhibitor0.9272
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.924
CYP450 2C9 substrateNon-substrate0.6878
CYP450 2D6 substrateNon-substrate0.8351
CYP450 3A4 substrateNon-substrate0.6789
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9602
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6885
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6469
BiodegradationNot ready biodegradable0.9881
Rat acute toxicity2.1362 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9342
hERG inhibition (predictor II)Non-inhibitor0.8525
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Astrazeneca lp
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • International medication system
  • Luitpold pharmaceuticals inc
  • Marsam pharmaceuticals llc
  • Organon usa inc
  • Smith and nephew solopak div smith and nephew
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Wockhardt ltd
  • Wyeth ayerst laboratories
  • Sanofi aventis us llc
  • Roxane laboratories inc
  • Wockhardt eu operations (swiss) ag
  • Dava pharmaceuticals inc
  • Excellium pharmaceutical inc
  • International medication systems ltd
  • Ipca laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kalapharm inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Superpharm corp
  • Vintage pharmaceuticals inc
  • County line pharmaceuticals llc
Packagers
Dosage forms
FormRouteStrength
Injectionintramuscular; intravenous10 mg/2mL
Injectionintramuscular; intravenous20 mg/2mL
Injectionintravenous10 mg/mL
Injection, solutionintramuscular; intravenous10 mg/mL
Injection, solutionintravenous10 mg/mL
Solutionoral10 mg/mL
Solutionoral40 mg/4mL
Solutionoral40 mg/5mL
Liquidintramuscular; intravenous10 mg
Solutionintramuscular; intravenous10 mg
Solutionintravenous10 mg
Liquidintravenous10 mg
Tabletoral80 mg
Tabletoral20 mg/1
Tabletoral40 mg/1
Tabletoral80 mg/1
Liquidoral10 mg
Solutionoral10 mg
Liquidintramuscular; intravenous20 mg
Tabletoral500 mg
Tabletoral20 mg
Tabletoral40 mg
Prices
Unit descriptionCostUnit
Hydro 40 40% Foam 150 gm Can182.52USD can
Hydro 40 40% Foam 70 gm Can148.99USD can
Furosemide 10 mg/ml Solution 60ml Bottle17.99USD bottle
Furosemide 10 mg/ml Solution 120ml Bottle15.98USD bottle
Furosemide powder3.51USD g
Lasix Special 500 mg Tablet3.25USD tablet
Urex 1 gm tablet2.47USD tablet
Furosemide 10 mg/ml cartrg1.45USD ml
Lasix 80 mg tablet1.0USD tablet
Furosemide 10 mg/ml Solution0.9USD ml
Furosemide 10 mg/ml0.75USD ml
Lasix 40 mg tablet0.53USD tablet
Furosemide 80 mg tablet0.45USD tablet
Lasix 20 mg tablet0.42USD tablet
Lasix 10 mg/ml Solution0.3USD ml
CVS Pharmacy diuretic 50 mg softgel0.17USD softgel capsule
Furosemide 40 mg tablet0.16USD tablet
Furosemide 20 mg tablet0.14USD tablet
Apo-Furosemide 80 mg Tablet0.13USD tablet
Novo-Semide 80 mg Tablet0.13USD tablet
Nat herbal diuretic tablet sa0.1USD tablet
Apo-Furosemide 40 mg Tablet0.07USD tablet
Natural herbal diuretic tablet0.07USD tablet
Novo-Semide 40 mg Tablet0.07USD tablet
Apo-Furosemide 20 mg Tablet0.05USD tablet
Novo-Semide 20 mg Tablet0.05USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point206U.S. Patent 3,058,882.
water solubility73.1 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.03SANGSTER (1993)
logS-3.66ADME Research, USCD
Caco2 permeability-6.5ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.118 mg/mLALOGPS
logP2.71ALOGPS
logP1.75ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)4.25ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area122.63 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity77.47 m3·mol-1ChemAxon
Polarizability30.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, N/A (Annotated)splash10-03dr-0090000000-da505a3f09285d049f34View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, N/A (Annotated)splash10-0f89-2190000000-53c91100e89c81f0fa30View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, N/A (Annotated)splash10-01ox-9660000000-83d8486cbca0dd3487c9View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Angelo Signor, Alfredo Guerrato, Giovanni Signor, “Process for the preparation of furosemide.” U.S. Patent US5739361, issued June, 1971.

US5739361
General References
  1. Rais-Bahrami K, Majd M, Veszelovszky E, Short BL: Use of furosemide and hearing loss in neonatal intensive care survivors. Am J Perinatol. 2004 Aug;21(6):329-32. [PubMed:15311369 ]
  2. Korpi ER, Kuner T, Seeburg PH, Luddens H: Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor. Mol Pharmacol. 1995 Feb;47(2):283-9. [PubMed:7870036 ]
  3. Tia S, Wang JF, Kotchabhakdi N, Vicini S: Developmental changes of inhibitory synaptic currents in cerebellar granule neurons: role of GABA(A) receptor alpha 6 subunit. J Neurosci. 1996 Jun 1;16(11):3630-40. [PubMed:8642407 ]
  4. Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ: Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit. Mol Pharmacol. 1996 Sep;50(3):670-8. [PubMed:8794909 ]
External Links
ATC CodesC03EB01C03CB01C03CA01
AHFS Codes
  • 40:28.08
PDB EntriesNot Available
FDA labelDownload (462 KB)
MSDSDownload (74.3 KB)
Interactions
Drug Interactions
Drug
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Furosemide.
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Furosemide.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Furosemide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Furosemide.
AlfuzosinAlfuzosin may increase the hypotensive activities of Furosemide.
AliskirenThe serum concentration of Furosemide can be decreased when it is combined with Aliskiren.
AllopurinolThe risk or severity of adverse effects can be increased when Furosemide is combined with Allopurinol.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Furosemide.
AmifostineFurosemide may increase the hypotensive activities of Amifostine.
AmikacinThe risk or severity of adverse effects can be increased when Furosemide is combined with Amikacin.
ArbekacinThe risk or severity of adverse effects can be increased when Furosemide is combined with Arbekacin.
BrimonidineBrimonidine may increase the antihypertensive activities of Furosemide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Furosemide.
ButabarbitalButabarbital may increase the hypotensive activities of Furosemide.
ButethalButethal may increase the hypotensive activities of Furosemide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Furosemide.
CaffeineThe risk or severity of adverse effects can be increased when Caffeine is combined with Furosemide.
CanagliflozinCanagliflozin may increase the hypotensive activities of Furosemide.
Chloral hydrateThe risk or severity of adverse effects can be increased when Furosemide is combined with Chloral hydrate.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Furosemide.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Furosemide.
CisplatinFurosemide may increase the nephrotoxic activities of Cisplatin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Furosemide.
ColesevelamColesevelam can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Furosemide.
DiazoxideDiazoxide may increase the hypotensive activities of Furosemide.
DigoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Furosemide.
DofetilideFurosemide may increase the QTc-prolonging activities of Dofetilide.
DuloxetineFurosemide may increase the orthostatic hypotensive activities of Duloxetine.
Etacrynic acidFurosemide may increase the ototoxic activities of Ethacrynic acid.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Furosemide.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Furosemide.
FlunisolideFlunisolide may increase the hypokalemic activities of Furosemide.
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Furosemide.
FosphenytoinFosphenytoin may decrease the diuretic activities of Furosemide.
FramycetinThe risk or severity of adverse effects can be increased when Furosemide is combined with Framycetin.
GentamicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Gentamicin.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Furosemide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Furosemide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Furosemide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Furosemide.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Furosemide.
HexobarbitalHexobarbital may increase the hypotensive activities of Furosemide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Furosemide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Furosemide.
InfliximabInfliximab may decrease the diuretic activities of Furosemide.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Furosemide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Furosemide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Furosemide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Furosemide.
Insulin HumanThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Furosemide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Furosemide.
IvabradineFurosemide may increase the arrhythmogenic activities of Ivabradine.
KanamycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Kanamycin.
LevodopaFurosemide may increase the orthostatic hypotensive activities of Levodopa.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Furosemide.
LicoriceLicorice may increase the hypokalemic activities of Furosemide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Furosemide.
LithiumThe serum concentration of Lithium can be decreased when it is combined with Furosemide.
MecamylamineThe risk or severity of adverse effects can be increased when Furosemide is combined with Mecamylamine.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Furosemide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Furosemide.
MethohexitalMethohexital may increase the hypotensive activities of Furosemide.
MethotrexateThe therapeutic efficacy of Furosemide can be decreased when used in combination with Methotrexate.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Furosemide.
MolsidomineMolsidomine may increase the hypotensive activities of Furosemide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Furosemide.
MoxonidineMoxonidine may increase the hypotensive activities of Furosemide.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Furosemide.
NeomycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Neomycin.
NetilmicinThe risk or severity of adverse effects can be increased when Furosemide is combined with Netilmicin.
NicorandilNicorandil may increase the hypotensive activities of Furosemide.
ObinutuzumabFurosemide may increase the hypotensive activities of Obinutuzumab.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Furosemide.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Furosemide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Furosemide.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Furosemide.
PentobarbitalPentobarbital may increase the hypotensive activities of Furosemide.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Furosemide.
PerindoprilFurosemide may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Furosemide.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Furosemide.
PhenytoinPhenytoin may decrease the diuretic activities of Furosemide.
PrimidonePrimidone may increase the hypotensive activities of Furosemide.
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Furosemide.
QuinineQuinine may increase the hypotensive activities of Furosemide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Furosemide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Furosemide.
RibostamycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Ribostamycin.
RisperidoneThe risk or severity of adverse effects can be increased when Furosemide is combined with Risperidone.
RituximabFurosemide may increase the hypotensive activities of Rituximab.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Furosemide.
SecobarbitalSecobarbital may increase the hypotensive activities of Furosemide.
SpectinomycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Spectinomycin.
StreptomycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Streptomycin.
SucralfateThe serum concentration of Furosemide can be decreased when it is combined with Sucralfate.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Furosemide.
SulpirideThe risk or severity of adverse effects can be increased when Furosemide is combined with Sulpiride.
TadalafilTadalafil may increase the antihypertensive activities of Furosemide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Furosemide.
TeriflunomideThe serum concentration of Furosemide can be increased when it is combined with Teriflunomide.
TobramycinThe risk or severity of adverse effects can be increased when Furosemide is combined with Tobramycin.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Furosemide.
TopiramateFurosemide may increase the hypokalemic activities of Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Furosemide.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Furosemide.
TreprostinilTreprostinil may increase the hypotensive activities of Furosemide.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Furosemide.
VardenafilVardenafil may increase the antihypertensive activities of Furosemide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Furosemide.
YohimbineYohimbine may decrease the antihypertensive activities of Furosemide.
Food Interactions
  • Avoid alcohol.
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Increase potassium intake; add a banana or orange juice; unless instructed otherwise.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Brater DC: Pharmacology of diuretics. Am J Med Sci. 2000 Jan;319(1):38-50. [PubMed:10653443 ]
  2. Davies DL, Wilson GM: Diuretics: mechanism of action and clinical application. Drugs. 1975;9(3):178-226. [PubMed:1092541 ]
  3. Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nurnberg P, Brockmoller J: Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. [PubMed:17460608 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Phosphogluconate dehydrogenase (decarboxylating) activity
Specific Function:
Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
Gene Name:
PGD
Uniprot ID:
P52209
Molecular Weight:
53139.56 Da
References
  1. Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [PubMed:20235752 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Lebedev AA, Samokrutova OV: [Study of the binding of diuretics by serum proteins according to changes in tryptophan fluorescence]. Farmakol Toksikol. 1989 May-Jun;52(3):40-3. [PubMed:2792351 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Kim GH, Na KY, Kim SY, Joo KW, Oh YK, Chae SW, Endou H, Han JS: Up-regulation of organic anion transporter 1 protein is induced by chronic furosemide or hydrochlorothiazide infusion in rat kidney. Nephrol Dial Transplant. 2003 Aug;18(8):1505-11. [PubMed:12897087 ]
  2. Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999 Jan;276(1 Pt 2):F122-8. [PubMed:9887087 ]
  3. Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [PubMed:9950961 ]
  4. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8. [PubMed:10727523 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A.
Gene Name:
SLCO2A1
Uniprot ID:
Q92959
Molecular Weight:
70043.33 Da
References
  1. Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL: Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9. [PubMed:7754369 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23